In 2017, WuXi STA merged with WuXi AppTec’s pharmaceutical development services unit. Two new commercial drug product facilities in Shanghai and Wuxi City have come into operation, enabling WuXi STA to support solid dosage drug development from preclinical to commercial, with several phase III and commercial drug product projects underway.
 
WuXi STA has received FDA inspections at both its API and advanced intermediate manufacturing facility in Jinshan (Shanghai), and API R&D and manufacturing facility in Changzhou. As a global contract development and manufacturing organization (CDMO), WuXi STA has passed inspections by regulatory bodies in the U.S., Canada, EU, Switzerland, China, Australia and New Zealand to supply APIs and GMP advanced intermediates for partners.
 
“We are very proud to have passed the European MPA GMP inspection,” said Mei Hao, vice president of quality, WuXi STA. “We will continue to strengthen our global quality control system to meet the most stringent regulatory requirements and ensure the quality of services to our partners worldwide. It is a key milestone in our efforts to build geographically integrated capabilities for both drug product and substance development and manufacturing.”